IL6 and inflammatory bowel disease: We found bulk mRNA-sequencing (bulk RNA-seq) data of colon mucosal biopsies from IBD patients enrolled in an open-label, prospective phase 2a trial, deposited as GSE171770 by Schreiber et al.31 In this study, 16 IBD patients with active disease, all of which experienced failure with conventional therapies, received the interleukin (IL-)6 trans-signalling inhibitor olamkicept.